Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10383392 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL11042224 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL20495959 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL14436836 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL24684882 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL22658086 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL24200454 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL22342116 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL22766465 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL20495968 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125031-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | Novosom AG (DE) | 2009-12-02 | — | — | EP | claimed |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | CEQUENT PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | claimed |
| EP-1938843-A1 | Lipids and lipid assemblies comrising transfection enhancer elements | Novosom AG (DE) | 2008-07-02 | — | — | EP | claimed |
| WO-2008074487-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | NOVOSOM AG (DE) | 2008-06-26 | — | — | WO | claimed |
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. | 2008-06-19 | — | — | US | claimed |
| US-7189705-B2 | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2007-03-13 | — | — | US | claimed |
| CN-117624029-A | Arylpyridine or arylpiperidine derivative or salt thereof, synthesis and application and medicine | 赣江中药创新中心 | 2024-03-01 | — | — | CN | disclosed |
| CN-115215800-B | Dibenzocyclyl-cyclic amino ether derivative or salt, and preparation method and application thereof | 赣江中药创新中心 | 2023-07-18 | — | — | CN | disclosed |
| CN-115215800-A | Dibenzocyclyl-cyclic amino ether derivative or salt and preparation method and application thereof | 赣江中药创新中心 | 2022-10-21 | — | — | CN | disclosed |
| US-9618653-B2 | Microelectronic environmental sensing module | STMICROELECTRONICS PTE LTD. (SG) | 2017-04-11 | — | — | US | disclosed |
| US-8193246-B2 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2011158257-A1 | PREPARATION PROCESS OF FESOTERODINE AND INTERMEDIATES | PANACEA BIOTEC LTD (IN) | 2011-12-22 | — | — | WO | disclosed |
| US-7723345-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1019358-B1 | 3,3-DIARYLPROPYLAMINES , THEIR USE AND PREPARATION | PHARMACIA AB (SE) | 2003-05-07 | — | — | EP | disclosed |
| US-6313132-B1 | FOR THERAPY OF URINARY INCONTINENCE, ACETYLCHOLINE-MEDIATED DISORDER | PHARMACIA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| US-6313132-B1 | FOR THERAPY OF URINARY INCONTINENCE, ACETYLCHOLINE-MEDIATED DISORDER | PHARMACIA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-1019358-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia & Upjohn AB (SE) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998043942-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-10-08 | — | — | WO | disclosed |
| US-4098890-A | METHOD FOR TREATING ARRHYTHMIA | ELI LILLY AND COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-3987201-A | ARYL AMINES | ELI LILLY AND COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | HNRNPH3, SREBF2, PHOSPHO1 | ALDH1A1 4867/4885TDP1 1475/4885LMNA 446/4885 |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | SREBF1, SREBF2, ELOVL1 | ALDH1A1 3614/4885TDP1 1587/4885LMNA 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.